FDA Introduces Optional Agentic AI Models to Assist Staff with Regulatory Tasks

The U.S. Food and Drug Administration (FDA) has introduced Agentic AI models to assist its staff in various regulatory tasks, including managing meetings, conducting pre-market reviews, and validating reports. The agency stated that the use of this technology is optional for employees and aims to streamline workflows as part of broader modernization efforts.

Agentic AI is designed to support FDA personnel by automating certain administrative and analytical processes. These models can facilitate meeting organization, enhance efficiency in reviewing pre-market submissions, and ensure accuracy in report validation. The FDA emphasized that the adoption of these tools remains voluntary for staff members, allowing them to choose whether or not to integrate the technology into their daily operations. This initiative reflects ongoing efforts by the agency to explore technological solutions for improving regulatory procedures while maintaining flexibility for its workforce.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Digital Transformation Cuts Generic Drug Development Costs, Improves Market Awareness. FDA Expands Label for GE HealthCare’s Vizamyl PET Agent to Aid Alzheimer’s Diagnostics New Topical Formulation Shows Potential for Relieving Chemotherapy-Induced Peripheral Neuropathy Symptoms Ultra-Mild Bisulfite Method Enhances Detection of 5-Methylcytosine in Low Input DNA Samples

Author

GOAI